Jack C. de la Torre
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Latest Publications
- 29 March 2018
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 63 (1) , 35-52
The Vascular Hypothesis of Alzheimer’s Disease: A Key to Preclinical Prediction of Dementia Using Neuroimaging
The vascular hypothesis of Alzheimer’s disease (VHAD) was proposed 24 years ago from observations made in our laboratory using aging rats subjected to chronic brain hypoperfusion. In recent years, VHAD has become a mother-lode to numerous neuroimaging studies targeting cerebral hemodynamic changes, particularly brain hypoperfusion in elderly patients at risk of developing Alzheimer’s disease (AD). There is a growing consensus among neuroradiologists that brain hypoperfusion is likely involved in the pathogenesis of AD and that disturbed cerebral blood flow (CBF) can serve as a key biomarker for predicting conversion of mild cognitive impairment to AD. The use of cerebral hypoperfusion as a preclinical predictor of AD is becoming decisive in stratifying low and high risk patients that may develop cognitive decline and for assessing the effectiveness of therapeutic interventions. There is currently an international research drive from neuroimaging groups to seek new perspectives that can broaden our understanding of AD and improve lifestyle. Diverse neuroimaging methods are currently being used to monitor normal and dyscognitive brain activity. Some techniques are very powerful and can detect, diagnose, quantify, prognose, and predict cognitive decline before AD onset, even from a healthy cognitive state. Multimodal imaging offers new insights in the treatment and prevention of cognitive decline during advanced aging and better understanding of the functional and structural organization of the human brain. This review discusses the impact the VHAD and CBF are having on the neuroimaging technology that can usher practical strategies to help prevent AD.
- 29 March 2018
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 63 (1) , 35-52
The Vascular Hypothesis of Alzheimer’s Disease: A Key to Preclinical Prediction of Dementia Using Neuroimaging
The vascular hypothesis of Alzheimer’s disease (VHAD) was proposed 24 years ago from observations made in our laboratory using aging rats subjected to chronic brain hypoperfusion. In recent years, VHAD has become a mother-lode to numerous neuroimaging studies targeting cerebral hemodynamic changes, particularly brain hypoperfusion in elderly patients at risk of developing Alzheimer’s disease (AD). There is a growing consensus among neuroradiologists that brain hypoperfusion is likely involved in the pathogenesis of AD and that disturbed cerebral blood flow (CBF) can serve as a key biomarker for predicting conversion of mild cognitive impairment to AD. The use of cerebral hypoperfusion as a preclinical predictor of AD is becoming decisive in stratifying low and high risk patients that may develop cognitive decline and for assessing the effectiveness of therapeutic interventions. There is currently an international research drive from neuroimaging groups to seek new perspectives that can broaden our understanding of AD and improve lifestyle. Diverse neuroimaging methods are currently being used to monitor normal and dyscognitive brain activity. Some techniques are very powerful and can detect, diagnose, quantify, prognose, and predict cognitive decline before AD onset, even from a healthy cognitive state. Multimodal imaging offers new insights in the treatment and prevention of cognitive decline during advanced aging and better understanding of the functional and structural organization of the human brain. This review discusses the impact the VHAD and CBF are having on the neuroimaging technology that can usher practical strategies to help prevent AD.
- 21 March 2017
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 57 (2) , 353-371
Are Major Dementias Triggered by Poor Blood Flow to the Brain? Theoretical Considerations
There is growing evidence that chronic brain hypoperfusion plays a central role in the development of Alzheimer’s disease (AD) long before dyscognitive symptoms or amyloid-β accumulation in the brain appear. This commentary proposes that dementia wit
- 21 March 2017
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 57 (2) , 353-371
Are Major Dementias Triggered by Poor Blood Flow to the Brain? Theoretical Considerations
There is growing evidence that chronic brain hypoperfusion plays a central role in the development of Alzheimer’s disease (AD) long before dyscognitive symptoms or amyloid-β accumulation in the brain appear. This commentary proposes that dementia wit
- 1 March 2017
- Published by Elsevier in Journal of Photochemistry and Photobiology B: Biology
- Vol. 168, 149-155
Treating cognitive impairment with transcranial low level laser therapy
- 1 March 2017
- Published by Elsevier in Journal of Photochemistry and Photobiology B: Biology
- Vol. 168, 149-155
Treating cognitive impairment with transcranial low level laser therapy
- 10 January 2017
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 38 (8) , 584-585
Cardiac dysfunction and cognitive decline.
- 10 January 2017
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 38 (8) , 584-585
Cardiac dysfunction and cognitive decline.
- 26 September 2016
- Published by Wiley in Brain Pathology
- Vol. 26 (5) , 618-631
Cerebral Perfusion Enhancing Interventions: A New Strategy for the Prevention of Alzheimer Dementia
Cardiovascular and cerebrovascular diseases are major risk factors in the development of cognitive impairment and Alzheimer's disease (AD). These cardio‐cerebral disorders promote a variety of vascular risk factors which in the presence of advancing age are prone to markedly reduce cerebral perfusion and create a neuronal energy crisis. Long‐term hypoperfusion of the brain evolves mainly from cardiac structural pathology and brain vascular insufficiency. Brain hypoperfusion in the elderly is strongly associated with the development of mild cognitive impairment (MCI) and both conditions are presumed to be precursors of Alzheimer dementia. A therapeutic target to prevent or treat MCI and consequently reduce the incidence of AD aims to elevate cerebral perfusion using novel pharmacological agents. As reviewed here, the experimental pharmaca include the use of Rho kinase inhibitors, neurometabolic energy boosters, sirtuins and vascular growth factors. In addition, a compelling new technique in laser medicine called photobiomodulation is reviewed. Photobiomodulation is based on the use of low level laser therapy to stimulate mitochondrial energy production non‐invasively in nerve cells. The use of novel pharmaca and photobiomodulation may become important tools in the treatment or prevention of cognitive decline that can lead to dementia.
- 26 September 2016
- Published by Wiley in Brain Pathology
- Vol. 26 (5) , 618-631
Cerebral Perfusion Enhancing Interventions: A New Strategy for the Prevention of Alzheimer Dementia
Cardiovascular and cerebrovascular diseases are major risk factors in the development of cognitive impairment and Alzheimer's disease (AD). These cardio‐cerebral disorders promote a variety of vascular risk factors which in the presence of advancing age are prone to markedly reduce cerebral perfusion and create a neuronal energy crisis. Long‐term hypoperfusion of the brain evolves mainly from cardiac structural pathology and brain vascular insufficiency. Brain hypoperfusion in the elderly is strongly associated with the development of mild cognitive impairment (MCI) and both conditions are presumed to be precursors of Alzheimer dementia. A therapeutic target to prevent or treat MCI and consequently reduce the incidence of AD aims to elevate cerebral perfusion using novel pharmacological agents. As reviewed here, the experimental pharmaca include the use of Rho kinase inhibitors, neurometabolic energy boosters, sirtuins and vascular growth factors. In addition, a compelling new technique in laser medicine called photobiomodulation is reviewed. Photobiomodulation is based on the use of low level laser therapy to stimulate mitochondrial energy production non‐invasively in nerve cells. The use of novel pharmaca and photobiomodulation may become important tools in the treatment or prevention of cognitive decline that can lead to dementia.
- 26 June 2016
- Published by Springer Nature
- p. 151-168
The Good, the Bad, and the Ugly of Advanced Aging
- 26 June 2016
- Published by Springer Nature
- p. 61-68
Alzheimer’s Noise
- 26 June 2016
- Published by Springer Nature
- p. 1-20
How Does Alzheimer’s Begin and Who Gets It?
- 26 June 2016
- Published by Springer Nature
- p. 31-38
Alzheimer’s Then and Now